<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/02/PT-2-25-02-2026-shutterstock_2284571133-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="430" height="241" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/02/PT-2-25-02-2026-shutterstock_2284571133-430x241.jpg"/></p>
<p>SLTE-1009 是一种单克隆抗体，旨在靶向 PACAP 以预防偏头痛和其他头痛疾病。图片来源：Komsan Loonprom / Shutterstock.com。</p>
<p>Slate Medicines 已获得 1.3 亿美元的 A 轮融资，旨在推进抗垂体腺苷酸酰化酶激活多肽（PACAP）偏头痛疗法。</p>
<p>这笔资金与 SLTE-1009 的许可使用相吻合，该抗 PACAP 单克隆抗体是从 DartsBio Pharmaceuticals（广东）获得的。</p>
<h3>深入了解 GlobalData</h3>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>报告</p>
<h4>LOA 和 PTSR 模型 - SL-172154 在骨髓增生异常综合症中的应用</h4>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>报告</p>
<h4>LOA 和 PTSR 模型 - SL-172154 在难治性急性髓性白血病中的应用</h4>
<h5>深入了解 GlobalData</h5>
<p>商业智能的黄金标准。</p>
<p>了解更多</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>发现高效的 B2B 营销</h4>
<p>结合商业智能和编辑卓越，覆盖 36 个领先媒体平台的专业人士。</p>
<p>了解更多</p>
<p>该公司由首席执行官兼董事会成员 Gregory Oakes 领导，他在临床阶段和商业生物制药组织中拥有超过 30 年的经验。</p>
<p>Oakes 曾担任 Raven（RA Capital 的医疗保健部门）的风险合伙人，并在 Celgene、Landos Biopharma、Vifor Pharma 和诺华担任高管职务。</p>
<p>Neil Buckley 在担任 Raven 的风险合伙人后加入公司，担任首席运营官和总裁。临床团队包括首席医学官 Roger Cady，他是头痛医学专家，曾担任 Alder Biopharmaceuticals 的神经学副总裁。</p>
<p>SLTE-1009 也被称为 DS009，是一种单克隆抗体，旨在靶向 PACAP 以预防偏头痛和其他头痛疾病。</p>
<p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData 战略情报</p>
<h1>美国关税正在变化 - 你会反应还是预见？</h1>
<p>不要让政策变化让你措手不及。通过实时数据和专家分析保持主动。</p>
<p>来自 GlobalData</p>
<p>了解更多关于战略情报</p>
<p>PACAP 被认为是一个与降钙素基因相关肽（CGRP）相比具有明显临床验证的靶点，可能为那些现有疗法效果不佳的患者提供益处。</p>
<p>SLTE-1009 采用了半衰期延长技术，允许皮下给药。Slate Medicines 还在开发另一个管线项目，具体细节尚未披露。</p>
<p>Oakes 表示：“凭借引人注目的生物学、差异化的产品特征和强大的投资者支持，Slate Medicines 有望重新定义需要新选择的患者的偏头痛预防。”</p>
<p>“我们相信 SLTE-1009 不仅为患者提供了一种新的偏头痛预防机制，还通过方便的家庭皮下给药改善了可及性。”</p>
<p>Cady 表示：“PACAP 阻断代表了一种临床验证的偏头痛预防方法。对于数百万对现有标准治疗反应不足的患者，我们相信 SLTE-1009 提供了一种新颖的、正交的方法来预防偏头痛。”</p>
<p>Andrew Levin（RA Capital）、Tim Lohoff（Forbion）和 Cindy Xiong（Foresite Capital）将在此次融资后加入 Slate Medicines 的董事会。</p>

福泰制药

SLRX

Blueprint医药

<p>Slate Medicines 在一轮 A 轮融资中筹集了 1.3 亿美元，以推进其抗 PACAP 偏头痛疗法，特别是单克隆抗体 SLTE-1009。这笔资金是在从 DartsBio Pharmaceuticals 获得 SLTE-1009 的许可后获得的。该公司旨在提供一种新颖的偏头痛预防机制，针对对现有治疗反应不佳的患者。首席执行官 Gregory Oakes 强调了 SLTE-1009 通过方便的皮下给药提高患者可及性的潜力。这轮融资还为董事会带来了来自 RA Capital、Forbion 和 Foresite Capital 的新成员</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/02/PT-2-25-02-2026-shutterstock_2284571133-430x241.jpg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/02/PT-2-25-02-2026-shutterstock_2284571133-430x241.jpg"/></p>
<p>SLTE-1009 is a monoclonal antibody developed to target PACAP to prevent migraines and other headache disorders. Credit: Komsan Loonprom / Shutterstock.com.</p>
<div class="lb-trans"><p>SLTE-1009 是一种单克隆抗体，旨在靶向 PACAP 以预防偏头痛和其他头痛疾病。图片来源：Komsan Loonprom / Shutterstock.com。</p>
</div><p>Slate Medicines has secured a $130m Series A financing round aimed at advancing anti-pituitary adenylate cyclase-activating polypeptide (PACAP) migraine therapies.</p>
<div class="lb-trans"><p>Slate Medicines 已获得 1.3 亿美元的 A 轮融资，旨在推进抗垂体腺苷酸酰化酶激活多肽（PACAP）偏头痛疗法。</p>
</div><p>The funding coincides with the in-licensing of SLTE-1009, an anti-PACAP monoclonal antibody acquired from DartsBio Pharmaceuticals (Guangdong).</p>
<div class="lb-trans"><p>这笔资金与 SLTE-1009 的许可使用相吻合，该抗 PACAP 单克隆抗体是从 DartsBio Pharmaceuticals（广东）获得的。</p>
</div><h3>Go deeper with GlobalData</h3>
<div class="lb-trans"><h3>深入了解 GlobalData</h3>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>报告</p>
</div><h4>LOA and PTSR Model - SL-172154 in Myelodysplastic Syndrome</h4>
<div class="lb-trans"><h4>LOA 和 PTSR 模型 - SL-172154 在骨髓增生异常综合症中的应用</h4>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>报告</p>
</div><h4>LOA and PTSR Model - SL-172154 in Refractory Acute Myeloid Leukemia</h4>
<div class="lb-trans"><h4>LOA 和 PTSR 模型 - SL-172154 在难治性急性髓性白血病中的应用</h4>
</div><h5>Go deeper with GlobalData</h5>
<div class="lb-trans"><h5>深入了解 GlobalData</h5>
</div><p>The gold standard of business intelligence.</p>
<div class="lb-trans"><p>商业智能的黄金标准。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>了解更多</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>Discover B2B Marketing That Performs</h4>
<div class="lb-trans"><h4>发现高效的 B2B 营销</h4>
</div><p>Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.</p>
<div class="lb-trans"><p>结合商业智能和编辑卓越，覆盖 36 个领先媒体平台的专业人士。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>了解更多</p>
</div><p>The company is headed by CEO and board director Gregory Oakes, who brings more than 30 years of experience from clinical-stage and commercial biopharma organisations.</p>
<div class="lb-trans"><p>该公司由首席执行官兼董事会成员 Gregory Oakes 领导，他在临床阶段和商业生物制药组织中拥有超过 30 年的经验。</p>
</div><p>Oakes previously worked as a venture partner at Raven, RA Capital’s healthcare arm, and held executive roles at Celgene, Landos Biopharma, Vifor Pharma, and Novartis.</p>
<div class="lb-trans"><p>Oakes 曾担任 Raven（RA Capital 的医疗保健部门）的风险合伙人，并在 Celgene、Landos Biopharma、Vifor Pharma 和诺华担任高管职务。</p>
</div><p>Neil Buckley has joined as COO and president after serving as a venture partner at Raven. The clinical team includes chief medical officer Roger Cady, a specialist in headache medicine and former neurology vice-president at Alder Biopharmaceuticals.</p>
<div class="lb-trans"><p>Neil Buckley 在担任 Raven 的风险合伙人后加入公司，担任首席运营官和总裁。临床团队包括首席医学官 Roger Cady，他是头痛医学专家，曾担任 Alder Biopharmaceuticals 的神经学副总裁。</p>
</div><p>Also referred to as DS009, SLTE-1009 is a monoclonal antibody developed to target PACAP to prevent migraines and other headache disorders.</p>
<div class="lb-trans"><p>SLTE-1009 也被称为 DS009，是一种单克隆抗体，旨在靶向 PACAP 以预防偏头痛和其他头痛疾病。</p>
</div><p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData Strategic Intelligence</p>
<div class="lb-trans"><p>GlobalData 战略情报</p>
</div><h1>US Tariffs are shifting - will you react or anticipate?</h1>
<div class="lb-trans"><h1>美国关税正在变化 - 你会反应还是预见？</h1>
</div><p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
<div class="lb-trans"><p>不要让政策变化让你措手不及。通过实时数据和专家分析保持主动。</p>
</div><p>By GlobalData</p>
<div class="lb-trans"><p>来自 GlobalData</p>
</div><p>Learn more about Strategic Intelligence</p>
<div class="lb-trans"><p>了解更多关于战略情报</p>
</div><p>PACAP is considered a distinct clinically validated target compared to calcitonin gene-related peptide (CGRP), possibly offering benefits for those not effectively treated by current therapies.</p>
<div class="lb-trans"><p>PACAP 被认为是一个与降钙素基因相关肽（CGRP）相比具有明显临床验证的靶点，可能为那些现有疗法效果不佳的患者提供益处。</p>
</div><p>SLTE-1009 incorporates half-life extension technology, allowing for subcutaneous dosing. Slate Medicines is also developing another pipeline project, details of which have not yet been disclosed.</p>
<div class="lb-trans"><p>SLTE-1009 采用了半衰期延长技术，允许皮下给药。Slate Medicines 还在开发另一个管线项目，具体细节尚未披露。</p>
</div><p>Oakes said: “With compelling biology, a differentiated product profile, and strong investor backing, Slate Medicines is positioned to redefine migraine prevention for patients who need new options.</p>
<div class="lb-trans"><p>Oakes 表示：“凭借引人注目的生物学、差异化的产品特征和强大的投资者支持，Slate Medicines 有望重新定义需要新选择的患者的偏头痛预防。”</p>
</div><p>“We believe that SLTE-1009 not only offers patients a novel mechanism for migraine prevention but also improved access through convenient at-home subcutaneous dosing.”</p>
<div class="lb-trans"><p>“我们相信 SLTE-1009 不仅为患者提供了一种新的偏头痛预防机制，还通过方便的家庭皮下给药改善了可及性。”</p>
</div><p>Cady said: “PACAP blockade represents a clinically validated approach for the prevention of migraine headaches. For the millions of patients with an inadequate response to the existing standard of care, we believe that SLTE-1009 offers a novel, orthogonal approach to preventing migraines.”</p>
<div class="lb-trans"><p>Cady 表示：“PACAP 阻断代表了一种临床验证的偏头痛预防方法。对于数百万对现有标准治疗反应不足的患者，我们相信 SLTE-1009 提供了一种新颖的、正交的方法来预防偏头痛。”</p>
</div><p>Andrew Levin (RA Capital), Tim Lohoff (Forbion), and Cindy Xiong (Foresite Capital) will join Slate Medicines’ Board of Directors following this financing round.</p>
<div class="lb-trans"><p>Andrew Levin（RA Capital）、Tim Lohoff（Forbion）和 Cindy Xiong（Foresite Capital）将在此次融资后加入 Slate Medicines 的董事会。</p>
</div>

Slate Medicines raises $130m in funds to progress anti-PACAP treatments

Pharmaceutical Technology

Salarius Pharmaceuticals

生物科技 ETF - VanEck Vectors

纽交所高增长板生物技术指数 ETF - First Trust

医药突破 ETF - ALPS

2 倍做多纳斯达克生物技术 ETF - ProShares

美国制药 ETF - iShares

动态生物技术与基因组 ETF - Invesco

医疗业 ETF - SPDR

Invesco Nasdaq Biotechnology ETF

基因改革 ETF - ARK

Slate Medicines 筹集 1.3 亿美元资金以推进抗 PACAP 治疗的进展